Blood Pressure Management in Hypertensive Heart Disease with CKD Stage 5

Introduction to Blood Pressure Targets

The American Journal of Kidney Diseases recommends targeting a blood pressure of <140/90 mmHg for patients with hypertensive heart disease and CKD stage 5, as the aggressive <120 mmHg target has no evidence base in this population and may cause harm 1, 2

CKD stage 5 patients were explicitly excluded from SPRINT, the trial that forms the basis for the <120 mmHg recommendation, making any extrapolation to this population unsupported by evidence 2
The KDIGO <120 mmHg recommendation does not apply to CKD stage 5 patients, as acknowledged by multiple guideline societies 1, 2

The European Society of Cardiology/European Society of Hypertension recommends systolic BP 130-139 mmHg for CKD patients, including stage 5 3, 2
The National Institute for Health and Care Excellence guidelines recommend <140/90 mmHg for CKD patients, with lower targets only justified for those with high albuminuria (ACR >70 mg/mmol) 2
Target <140/90 mmHg is the most appropriate goal based on available evidence and international consensus 1, 4, 2

ACE inhibitors or ARBs should be first-line therapy once blood pressure control is initiated, particularly if proteinuria is present 5, 1
Multiple antihypertensive agents are typically required to achieve target BP in CKD stage 5 patients 3
Thiazide diuretics, calcium channel blockers, and ACE inhibitors/ARBs are appropriate first-line agents, with thiazide diuretics or calcium channel blockers preferred as initial therapy in Black patients 4

Never apply the KDIGO <120 mmHg target to CKD stage 5 patients, as they were excluded from the supporting evidence and face increased risks of adverse events 3, 2
Avoid excessive diastolic BP lowering (<70 mmHg), which increases cardiovascular risk in CKD patients 3, 6
Do not aggressively lower BP to chronic targets during acute hypertensive emergencies, as this risks catastrophic hypoperfusion in patients with impaired autoregulation 3
Avoid simultaneous use of ACE inhibitor, ARB, and/or renin inhibitor, as this is potentially harmful 1

Monitor serum creatinine and potassium within 2-4 weeks of initiating ACE inhibitors or ARBs 3
For patients with proteinuria >300 mg/day, more intensive BP control toward <130/80 mmHg may be considered, but this should be balanced against the risks in advanced CKD 5, 1

The American College of Cardiology recommends careful consideration of the benefits and risks of BP targets in CKD stage 5 patients, given the lack of evidence for aggressive BP lowering 1
The JNC-8 guidelines recommended <140/90 mmHg for CKD patients of all ages, citing lack of evidence that lower targets reduce stroke, heart disease, mortality, or kidney failure 5, 4